| $350M | ||
| $241M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $13,308,479 | 22 | 100 |
| TORRES ARTHUR A | director | 0 | $0 | 2 | $214,676 | $-214,676 |
| Novack Jeffrey Adam | Secretary and General Counsel | 0 | $0 | 5 | $452,744 | $-452,744 |
| COURNOYER CHRISTINE | director | 0 | $0 | 1 | $750,973 | $-750,973 |
| Bickerstaff George | director | 0 | $0 | 1 | $925,700 | $-925,700 |
| Valantine Hannah | director | 0 | $0 | 2 | $1.32M | $-1.32M |
| Goldberg Michael | director | 0 | $0 | 1 | $2.1M | $-2.1M |
| Hanna John Walter JR | President and CEO | 0 | $0 | 10 | $7.54M | $-7.54M |
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Over the last 12 months, insiders at CareDx, Inc have bought $0 and sold $13.31M worth of CareDx, Inc stock.
On average, over the past 5 years, insiders at CareDx, Inc have bought $211,694 and sold $5.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $211,694 was made by Dhingra Ankur (Chief Financial Officer) on 2021‑11‑24.
| 2026-08-05 | Sale | Bickerstaff George | director | 20,000 0.0393% | $46.28 | $925,700 | +21.78% | |
| 2026-08-05 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 2,688 0.0053% | $46.26 | $124,349 | +21.78% | |
| 2026-08-04 | Sale | Goldberg Michael | director | 44,700 0.0863% | $47.06 | $2.1M | +15.37% | |
| 2026-08-04 | Sale | COURNOYER CHRISTINE | director | 16,000 0.0308% | $46.94 | $750,973 | +15.37% | |
| 2026-07-16 | Sale | Hanna John Walter JR | President and CEO | 118,000 0.214% | $37.79 | $4.46M | +29.81% | |
| 2026-07-16 | Sale | Valantine Hannah | director | 28,779 0.0499% | $36.15 | $1.04M | +29.81% | |
| 2026-06-29 | Sale | Hanna John Walter JR | President and CEO | 39,900 0.0771% | $29.24 | $1.17M | +71.40% | |
| 2026-06-26 | Sale | Hanna John Walter JR | President and CEO | 100 0.0002% | $29.00 | $2,900 | +73.87% | |
| 2026-06-15 | Sale | Hanna John Walter JR | President and CEO | 17,683 0.0342% | $24.03 | $424,877 | +106.77% | |
| 2026-06-15 | Sale | Valantine Hannah | director | 12,103 0.0225% | $23.11 | $279,728 | +106.77% | |
| 2026-06-11 | Sale | Hanna John Walter JR | President and CEO | 21,998 0.0432% | $24.02 | $528,443 | +109.64% | |
| 2026-06-04 | Sale | Hanna John Walter JR | President and CEO | 4,835 0.0097% | $24.00 | $116,045 | +108.61% | |
| 2026-05-15 | Sale | TORRES ARTHUR A | director | 6,484 0.0125% | $19.89 | $128,978 | +135.70% | |
| 2026-05-14 | Sale | TORRES ARTHUR A | director | 4,086 0.0081% | $20.97 | $85,698 | +129.53% | |
| 2026-05-05 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 2,688 0.0052% | $20.68 | $55,581 | +124.06% | |
| 2026-04-16 | Sale | Hanna John Walter JR | President and CEO | 10,282 0.0188% | $21.12 | $217,156 | +78.57% | |
| 2026-02-03 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 4,441 0.0086% | $20.56 | $91,286 | +29.20% | |
| 2026-01-22 | Sale | Hanna John Walter JR | President and CEO | 19,280 0.0377% | $21.16 | $408,023 | +13.56% | |
| 2026-01-21 | Sale | Hanna John Walter JR | President and CEO | 200 0.0004% | $21.00 | $4,200 | +13.59% | |
| 2026-01-15 | Sale | Hanna John Walter JR | President and CEO | 10,156 0.0202% | $21.05 | $213,804 | +14.10% |
| Hanna John Walter JR | President and CEO | 653448 1.2436% | $51.33M | 0 | 10 | |
| Bickerstaff George | director | 134061 0.2551% | $10.53M | 0 | 7 | |
| Novack Jeffrey Adam | Secretary and General Counsel | 106075 0.2019% | $8.33M | 0 | 12 | |
| Goldberg Michael | director | 61738 0.1175% | $4.85M | 1 | 13 | <0.0001% |
| COURNOYER CHRISTINE | director | 42943 0.0817% | $3.37M | 0 | 3 | |
| TORRES ARTHUR A | director | 38665 0.0736% | $3.04M | 1 | 2 | <0.0001% |
| Valantine Hannah | director | 36686 0.0698% | $2.88M | 0 | 3 | |
| TPG Group Holdings (SBS) Advisors, Inc. | 10 percent owner | 1075090 2.0461% | $84.46M | 1 | 0 | <0.0001% |
| BYERS BROOK H | 751174 1.4296% | $59.01M | 1 | 0 | <0.0001% | |
| KLEINER PERKINS CAUFIELD & BYERS X A LP | 10 percent owner | 751174 1.4296% | $59.01M | 1 | 0 | <0.0001% |
| Seeto Reginald | See Remarks | 479164 0.912% | $37.64M | 0 | 34 | |
| Jain Abhishek | Chief Financial Officer | 337418 0.6422% | $26.51M | 0 | 1 | |
| Maag Peter | director | 308846 0.5878% | $24.26M | 4 | 58 | +57.09% |
| Johnson Alexander L | See Remarks | 284983 0.5424% | $22.39M | 0 | 3 | |
| Gagnon Neil | 10 percent owner | 107940 0.2054% | $8.48M | 48 | 1 | +71.45% |
| Bell Michael Brian | Chief Financial Officer | 103343 0.1967% | $8.12M | 1 | 10 | +288.89% |
| Nelles Mitchell J | Chief Operating Officer | 85160 0.1621% | $6.69M | 1 | 2 | <0.0001% |
| HAGSTROM WILLIAM A | director | 53979 0.1027% | $4.24M | 0 | 8 | |
| SNYDERMAN RALPH | director | 51015 0.0971% | $4.01M | 0 | 5 | |
| Yee James P | Chief Medical Officer | 42045 0.08% | $3.3M | 0 | 5 | |
| King Sasha | Chief Marketing Officer | 40139 0.0764% | $3.15M | 0 | 16 | |
| Whitson Todd | Chief Commercial Officer | 10000 0.019% | $785,600.00 | 1 | 0 | <0.0001% |
| LUDLUM KEN | Chief Financial officer | 5000 0.0095% | $392,800.00 | 1 | 0 | <0.0001% |
| Dhingra Ankur | Chief Financial Officer | 5000 0.0095% | $392,800.00 | 1 | 0 | <0.0001% |
| Colon Grace | 4864 0.0093% | $382,115.84 | 0 | 3 |
| Increased Positions | 105 | +49.3% | 7M | +12.88% |
| Decreased Positions | 90 | -42.25% | 7M | -13.41% |
| New Positions | 44 | New | 2M | New |
| Sold Out Positions | 27 | Sold Out | 1M | Sold Out |
| Total Postitions | 228 | +7.04% | 53M | -0.53% |
| Blackrock, Inc. | $91,239.00 | 9.35% | 4.77M | +108,998 | +2.34% | 2025-09-30 |
| Vanguard Group Inc | $71,769.00 | 7.35% | 3.75M | -1M | -23.64% | 2025-09-30 |
| Bamco Inc /Ny/ | $60,390.00 | 6.19% | 3.16M | +719,523 | +29.54% | 2025-09-30 |
| State Street Corp | $49,122.00 | 5.03% | 2.57M | +386,304 | +17.72% | 2025-09-30 |
| Ophir Asset Management Pty Ltd | $42,069.00 | 4.31% | 2.2M | +304,953 | +16.11% | 2025-09-30 |
| Deerfield Management Company, L.P. | $41,936.00 | 4.3% | 2.19M | +2M | New | 2025-09-30 |
| Braidwell Lp | $41,778.00 | 4.28% | 2.18M | +2M | New | 2025-09-30 |
| Ark Investment Management Llc | $41,546.00 | 4.26% | 2.17M | +70,468 | +3.35% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $33,305.00 | 3.41% | 1.74M | +503,136 | +40.68% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $33,305.00 | 3.41% | 1.74M | +504,473 | +40.83% | 2025-09-30 |